Atea Pharmaceuticals (AVIR) investor relations material

Executive summary

• Two pivotal Phase 3 HCV trials (C-BEYOND and C-FORWARD) are progressing, with topline results expected mid-2026 and year-end 2026; NDA submission targeted for Q1–March 2027.

• Enrollment for both Phase 3 HCV trials is nearly complete, covering diverse genotypes and patient populations, with over 1,760 patients globally.

• The antiviral pipeline expanded to include AT-587 for chronic hepatitis E, with Phase 1 initiation planned for mid-2026 and proof-of-concept by year-end.

• No products approved or commercial revenue to date; all resources directed toward R&D and clinical advancement.

• Commercial launch preparations and supply production for the HCV regimen are underway, focusing on payer access and market penetration.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $256 million at March 31, 2026, down from $301.8 million at year-end 2025.

• Net loss for Q1 2026 was $45.4 million, compared to $34.3 million in Q1 2025, driven by increased R&D expenses.

• Operating expenses rose to $48.0 million from $39.0 million year-over-year, mainly due to higher external spend on HCV and HEV programs.

• General and administrative expenses decreased, mainly due to lower salaries, stock-based compensation, and professional fees.

• No revenue generated; interest income and other, net, decreased to $2.6 million from $5.0 million year-over-year.

Outlook and guidance

• Topline Phase 3 results for C-BEYOND expected mid-2026; C-FORWARD results anticipated around year-end 2026.

• NDA submission for HCV regimen anticipated in Q1–March 2027.

• Phase 1 clinical program for AT-587 in HEV is anticipated to begin mid-2026, with proof-of-concept study planned by year-end.

• Cash runway projected through 2027, supporting completion of HCV and advancement of HEV programs.

• No product revenue anticipated until at least 2027, pending successful clinical results and regulatory approvals.